Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current modalities in arthritic diseases.

T G Kantor1

  • 1New York University Medical Center, New York 10016.

The American Journal of Medicine
|October 30, 1987
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Current nonsteroidal anti-inflammatory drug applications for rheumatic diseases.

Primary care·1993
Same author

The pharmacological control of musculoskeletal pain.

Canadian journal of physiology and pharmacology·1991
Same author

Order out of chaos--the primary mission of the pyramid.

The Journal of rheumatology·1990
Same author

Concepts in pain control.

Seminars in arthritis and rheumatism·1989
Same author

The management of pain by pharmacological agents.

The Clinical journal of pain·1989
Same author

Chemical mediators and treatment of pain in rheumatic disease.

Bailliere's clinical rheumatology·1987
Same journal

Mineralocorticoid Antagonists for Post-MI HFpEF: Plausible Biology Meets Low Residual Risk?

The American journal of medicine·2026
Same journal

GLP-1 Receptor Agonists and Age-related Macular Degeneration Risk in Diabetes or Non-diabetic Obesity: A Retrospective Cohort Study.

The American journal of medicine·2026
Same journal

Marijuana Use and Acute Myocardial Infarction: Mechanistic Insights, Clinical Implications, and Emerging Challenges.

The American journal of medicine·2026
Same journal

Cave Canem - Beware of the Dog.

The American journal of medicine·2026
Same journal

Risk Factors for 30-day Hospital Readmission After Hospital-at-Home Treatment of Acute Pyelonephritis.

The American journal of medicine·2026
Same journal

Mesenteric panniculitis.

The American journal of medicine·2026
See all related articles

Identifying the causes of rheumatologic diseases remains challenging, limiting treatment options. However, significant progress has been made in managing symptoms with drugs like nonsteroidal anti-inflammatory drugs (NSAIDs).

Area of Science:

  • Rheumatology
  • Pharmacology
  • Neurobiology

Background:

  • Etiologies of major rheumatologic diseases remain largely unknown, hindering the development of disease-modifying treatments.
  • Significant advancements have been achieved in managing the signs and symptoms of these conditions.
  • Nonsteroidal anti-inflammatory drugs (NSAIDs) are the primary treatment for arthritis, with ongoing research into their mechanisms.

Purpose of the Study:

  • To review current understanding of NSAID mechanisms in suppressing arthritis inflammation and pain.
  • To highlight inconsistencies in current knowledge and the potential role of neurobiology.
  • To discuss the rationale for continued NSAID development and the need for safer alternatives.

Main Methods:

  • Literature review of rheumatologic disease treatments.

Related Experiment Videos

  • Analysis of current understanding of nonsteroidal anti-inflammatory drug (NSAID) mechanisms.
  • Exploration of neurobiological findings relevant to arthritis pain and inflammation.

    • Main Results:

    • Methotrexate is gaining acceptance as a second-line therapy for rheumatoid arthritis.
    • Nonsteroidal anti-inflammatory drugs (NSAIDs) are effective first-line treatments for arthritis symptoms.
    • Gastrointestinal intolerance contributes to noncompliance with NSAIDs, necessitating safer drug development.

    Conclusions:

    • Despite limited understanding of disease etiology, symptom management in rheumatologic diseases has advanced.
    • Continued development of nonsteroidal anti-inflammatory drugs (NSAIDs) is warranted, focusing on improved safety profiles.
    • New compounds are needed to address patient noncompliance due to gastrointestinal side effects.